Answers are grounded in this paper and cite their sources.
Retrospective analysis predicts COVID-19 mortality risk in chronic kidney disease patients, suggesting improved clinical decisions.
Objective: COVID-19 disease has a high prevalence and mortality rate among chronic kidney disease patients. Previous studies have shown that ML-based prediction models are effective for developing preventive strategies. Despite several efforts to establish prediction models for COVID-19 mortality risk among different populations, few studies have focused on COVID-19 mortality among patients with chronic kidney disease. The current study aimed to develop an effective, efficient preventive strategy to improve prognosis and survival among these patients by constructing a machine-learning-based prediction model. Methods: The current retrospective study used single-center data from 556 hospitalized patients with CKD. All patients in the cohort had respiratory failure following COVID-19. We leveraged ensemble and non-ensemble algorithms to construct a prediction model and scored the chosen features for better interpretability. Results: The empirical results of this study showed that XG-Boost achieved an AU-ROC of 0.921 with a 95% CI of [0.906-0.941] and an AU-ROC of 0.851 with a 95% CI of [0.835-0.877] in training and validation modes, respectively, yielding more favourable predictive performance than the models. Conclusion: XG-Boost demonstrated predictive merit that can be leveraged as an auxiliary tool to aid clinicians in making more informed decisions in clinical settings.
No takes yet. Share an insight, caveat, or question.
Raoof Nopour (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: